Paid Clinical Trials in Lawrence, KS
As of August 2026, 48 paid clinical trials are recruiting in Lawrence, Kansas. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Lawrence offers studies at sites including Lawrence Memorial Hospital for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Recurrent Lung Non-Small Cell Carcinoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Lawrence
Trials by drug in Lawrence
Filter results
48 clinical trials
Acellular Dermal Matrix Investigation in Breast Reconstruction
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Optimizing a Sensor-Enabled mHealth Intervention for Adolescents With Suboptimal Asthma Control
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Top Research Study Locations in Lawrence
Researchers run research studies in Lawrence, KS at 9 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Lawrence Memorial Hospital | Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm | 36 |
| University of Kansas | AML With Gene Mutations, Breast Reconstruction, Parkinson's Disease | 5 |
| Kansas University Medical Center | Heart Defects, Congenital, Heart Diseases, Heart Failure | 1 |
| University of Kanas | Asthma (Diagnosis) | 1 |
| University of Kansas Comprehension and Language Learning Lab | Autism Spectrum Disorder | 1 |
| University of Kansas Medical Center | Bladder Cancer | 1 |
| University of Kansas Medical Center Research Institute, Inc. | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | 1 |
| University of Kansas, Center for Research | Autism Spectrum Disorder | 1 |
| University of Kansas, Wakarusa Research Facility | Binge-Eating Disorder, Eating Disorders (Excluding Anorexia Nervosa) | 1 |
Active & Upcoming Studies in Lawrence (2026)
Recruiting trials in Lawrence grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (35 active studies)
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · Revolution Medicines, Inc.
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer · Phase 3 · National Cancer Institute (NCI)
Mental health & behavior (1 active study)
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Neurology & pain (1 active study)
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO · Phase 1 · National Cancer Institute (NCI)
Cardiovascular (1 active study)
- Global Utilization And Registry Database for Improved heArt preservatioN · Paragonix Technologies
Common conditions studied in Lawrence
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Lung Non-Small Cell Carcinoma (3 active studies)
- Malignant Solid Neoplasm (3 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
- Stage IV Lung Cancer AJCC v8 (3 active studies)
- Advanced Esophageal Adenocarcinoma (2 active studies)
Leading research sponsors in Lawrence
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- NRG Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Lawrence?
There are approximately 48 recruiting clinical trials in Lawrence, Kansas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Lawrence pay participants?
Most recruiting trials in Lawrence compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Lawrence?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Lawrence?
The most common conditions under active study in Lawrence include Anatomic Stage II Breast Cancer AJCC v8 (4), Lung Non-Small Cell Carcinoma (3), Malignant Solid Neoplasm (3), Recurrent Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Lawrence?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Lawrence on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Lawrence?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Lawrence?
Recruiting research sites in Lawrence include Lawrence Memorial Hospital, University of Kansas, Kansas University Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Lawrence right now?
The largest active categories in Lawrence are Cancer & tumors (35), Mental health & behavior (1), Neurology & pain (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.